Trial Profile
A Double-Blind Randomised 2-Arm, 2-Period Crossover Study to Access the Similarity of Safety and Pharmacokinetics of JHL1922 and Pulmozyme® After Single and Repeated Administration in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs Dornase alfa (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eden Biologics; JHL Biotech
- 05 Jan 2020 Status changed from recruiting to completed.
- 01 Mar 2018 According to a JHL Biotech media release, the Dutch Healthcare Authority has approved the Clinical Trial Application (CTA) for JHL1922 facilitating initiation of this trial in Netherlands in March 2018.
- 22 Feb 2018 Status changed from planning to recruiting, as reported in a JHL Biotech media release.